secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001193125-24-193412
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio Q2 net loss $462.5M on $425.1M AnHeart charge; halts NUV-868 Phase 2
--------------------------------------------------------------------------------

- Net loss of $462.5M ($1.89/share) vs. $20.6M ($0.09) Q2 2023; includes $425.1M acquired IPR&D charge from AnHeart acquisition.
- Cash, equivalents, and marketable securities of $577.2M as of June 30, 2024.
- R&D expenses $29.2M (up 57% YoY) and G&A $16.1M (up 115% YoY) partly due to AnHeart.
- Decided not to initiate Phase 2 for NUV-868 in prior solid tumor indications; evaluating next steps.
- Taletrectinib NDA planned in U.S. in 2025 based on pooled TRUST-I/II data at ESMO 2024; received FDA Orphan Drug Designation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524193412/0001193125-24-193412-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524193412/d867853d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-193412

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer